Jacc: Cardiooncology最新文献

{"title":"Full Issue PDF","authors":"","doi":"10.1016/S2666-0873(24)00261-8","DOIUrl":"10.1016/S2666-0873(24)00261-8","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages I-CLX"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324002618/pdfft?md5=6570b0cd1d87926630142b8ef929f6c1&pid=1-s2.0-S2666087324002618-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142011559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Light-Chain Pericardial Amyloidosis Emerging Alongside Variant Transthyretin Cardiac Amyloidosis","authors":"Alexander H. Gunn MD , Johana Fajardo DNP , Louis Dibernardo MD , Carolyn Glass MD , Fawaz Alenezi MD , Ravi Karra MD , Ellen D. McPhail MD , Cristiana Costa Chase DO , Michel G. Khouri MD","doi":"10.1016/j.jaccao.2024.04.002","DOIUrl":"10.1016/j.jaccao.2024.04.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 612-616"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324001467/pdfft?md5=f46fbc76d6a79bf174a7225c5a692b99&pid=1-s2.0-S2666087324001467-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mediterranean Diet Is Associated With Lower All-Cause and Cardiovascular Mortality Among Long-Term Cancer Survivors","authors":"Marialaura Bonaccio PhD , Augusto Di Castelnuovo PhD , Simona Costanzo PhD , Emilia Ruggiero PhD , Simona Esposito MSc , Teresa Panzera BSc , Chiara Cerletti PhD , Maria Benedetta Donati MD, PhD , Giovanni de Gaetano MD, PhD , Licia Iacoviello MD, PhD","doi":"10.1016/j.jaccao.2024.05.012","DOIUrl":"10.1016/j.jaccao.2024.05.012","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 602-604"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324002084/pdfft?md5=162cc2097081edc9d019deb80b882cc2&pid=1-s2.0-S2666087324002084-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141690389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Certainty of Evidence on Efficacy and Safety of Anticoagulants for Cancer-Associated Thrombosis","authors":"Faizan Khan PhD, Marc Carrier MD, Bram Rochwerg MD","doi":"10.1016/j.jaccao.2024.03.014","DOIUrl":"10.1016/j.jaccao.2024.03.014","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 622-623"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324002138/pdfft?md5=99de16470585e53cfaaafab04d244bdc&pid=1-s2.0-S2666087324002138-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141702553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy","authors":"Sara-Lise Busschaert MSc ,&nbsp;Eva Kimpe MSc ,&nbsp;Thierry Gevaert PhD ,&nbsp;Mark De Ridder PhD, MD ,&nbsp;Koen Putman PhD","doi":"10.1016/j.jaccao.2024.04.009","DOIUrl":"10.1016/j.jaccao.2024.04.009","url":null,"abstract":"<div><h3>Background</h3><p>Deep inspiration breath hold (DIBH) is an effective technique for reducing heart exposure during radiotherapy for left-sided breast cancer. Despite its benefits, cost considerations and its impact on workflow remain significant barriers to widespread adoption.</p></div><div><h3>Objectives</h3><p>This study aimed to assess the cost-effectiveness of DIBH and compare its operational, financial, and clinical outcomes with free breathing (FB) in breast cancer treatment.</p></div><div><h3>Methods</h3><p>Treatment plans for 100 patients with left-sided breast cancer were generated using both DIBH and FB techniques. Dosimetric data, including the average mean heart dose, were calculated for each technique and used to estimate the cardiotoxicity of radiotherapy. A state-transition microsimulation model based on SCORE2 (Systematic Coronary Risk Evaluation) algorithms projected the effects of DIBH on cardiovascular outcomes and quality-adjusted life-years (QALYs). Costs were calculated from a provider perspective using time-driven activity-based costing, applying a willingness-to-pay threshold of €40,000 for cost-effectiveness assessment. A discrete event simulation model assessed the impacts of DIBH vs FB on throughput and waiting times in the radiotherapy workflow.</p></div><div><h3>Results</h3><p>In the base case scenario, DIBH was associated with an absolute risk reduction of 1.72% (95% CI: 1.67%-1.76%) in total cardiovascular events and 0.69% (95% CI: 0.67%-0.72%) in fatal cardiovascular events over 20 years. Additionally, DIBH was estimated to provide an incremental 0.04 QALYs (95% CI: 0.05-0.05) per left-sided breast cancer patient over the same time period. However, DIBH increased treatment times, reducing maximum achievable throughput by 12.48% (95% CI: 12.36%-12.75%) and increasing costs by €617 per left-sided breast cancer patient (95% CI: €615-€619). The incremental cost-effectiveness ratio was €14,023 per QALY.</p></div><div><h3>Conclusions</h3><p>Despite time investments, DIBH is cost-effective in the Belgian population. The growing adoption of DIBH may benefit long-term cardiovascular health in breast cancer survivors.</p></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 514-525"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324002059/pdfft?md5=ef3a028ea334721f506bbe0608f82cfc&pid=1-s2.0-S2666087324002059-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141709101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Disease After Hematopoietic Stem Cell Transplantation in Adults","authors":"David G. Gent MBChB (Hons) ,&nbsp;Muhammad Saif MD ,&nbsp;Rebecca Dobson MD ,&nbsp;David J. Wright MD","doi":"10.1016/j.jaccao.2024.06.004","DOIUrl":"10.1016/j.jaccao.2024.06.004","url":null,"abstract":"<div><p>The use of hematopoietic cell transplantation (HCT) has expanded in the last 4 decades to include an older and more comorbid population. These patients face an increased risk of cardiovascular disease after HCT. The risk varies depending on several factors, including the type of transplant (autologous or allogeneic). Many therapies used in HCT have the potential to be cardiotoxic. Cardiovascular complications after HCT include atrial arrhythmias, heart failure, myocardial infarction, and pericardial effusions. Before HCT, patients should undergo a comprehensive cardiovascular assessment, with ongoing surveillance tailored to their individual level of cardiovascular risk. In this review, we provide an overview of cardiotoxicity after HCT and outline our approach to risk assessment and ongoing care.</p></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 475-495"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324002254/pdfft?md5=558e4c6d9d6c3badd123dba5ccbab081&pid=1-s2.0-S2666087324002254-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142011393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating Macrotroponin Complexes and Their Impact on Cardiac Troponin Measurements","authors":"Inbar Nardi-Agmon MD, MPH ,&nbsp;Ashley Di Meo PhD ,&nbsp;Leo Lam MBChB ,&nbsp;Campbell Kyle MBChB, PhD ,&nbsp;Husam Abdel-Qadir MD, PhD ,&nbsp;Eitan Amir MD, PhD ,&nbsp;Paaladinesh Thavendiranathan MD, SM","doi":"10.1016/j.jaccao.2024.06.002","DOIUrl":"10.1016/j.jaccao.2024.06.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 608-611"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324002229/pdfft?md5=4ed24702d6fc374028f1459b88bed3ac&pid=1-s2.0-S2666087324002229-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Benign Metastatic Leiomyoma","authors":"","doi":"10.1016/j.jaccao.2024.03.011","DOIUrl":"10.1016/j.jaccao.2024.03.011","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 617-621"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324001443/pdfft?md5=223627642c0462ed5b6de646943a7226&pid=1-s2.0-S2666087324001443-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141058048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to Rethink Using Cardiovascular Risk Scores for Cancer Survivors","authors":"Katrina K. Poppe PhD","doi":"10.1016/j.jaccao.2024.07.006","DOIUrl":"10.1016/j.jaccao.2024.07.006","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 589-591"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324002278/pdfft?md5=ee71be796de2e752935ca8198a49de72&pid=1-s2.0-S2666087324002278-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142011394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy","authors":"Katelyn M. Atkins MD, PhD ,&nbsp;Samuel C. Zhang MD ,&nbsp;Christopher Kehayias PhD ,&nbsp;Christian Guthier PhD ,&nbsp;John He BA ,&nbsp;Jordan O. Gasho BS ,&nbsp;Mina Bakhtiar MD ,&nbsp;Katrina D. Silos BA ,&nbsp;David E. Kozono MD, PhD ,&nbsp;Paul C. Zei MD ,&nbsp;Anju Nohria MD ,&nbsp;Andriana P. Nikolova MD, PhD ,&nbsp;Raymond H. Mak MD","doi":"10.1016/j.jaccao.2024.07.005","DOIUrl":"10.1016/j.jaccao.2024.07.005","url":null,"abstract":"<div><h3>Background</h3><p>Arrhythmias are common following radiotherapy for non–small cell lung cancer.</p></div><div><h3>Objectives</h3><p>The aim of this study was to analyze the association of distinct arrhythmia classes with cardiac substructure radiotherapy dose.</p></div><div><h3>Methods</h3><p>A retrospective analysis was conducted of 748 patients with locally advanced non–small cell lung cancer treated with radiotherapy. Cardiac substructure dose parameters were calculated. Receiver-operating characteristic curve analyses for predictors of Common Terminology Criteria for Adverse Events grade ≥3 atrial fibrillation (AF), atrial flutter, non-AF and non–atrial flutter supraventricular tachyarrhythmia (SVT), bradyarrhythmia, and ventricular tachyarrhythmia (VT) or asystole were calculated. Fine-Gray regression models were performed (with noncardiac death as a competing risk).</p></div><div><h3>Results</h3><p>Of 748 patients, 128 (17.1%) experienced at least 1 grade ≥3 arrhythmia, with a median time to first arrhythmia of 2.0 years (Q1-Q3: 0.9-4.2 years). The 2-year cumulative incidences of each arrhythmia group were 8.0% for AF, 2.7% for atrial flutter, 1.8% for other SVT, 1.4% for bradyarrhythmia, and 1.1% for VT or asystole. Adjusting for baseline cardiovascular risk, pulmonary vein (PV) volume receiving 5 Gy was associated with AF (subdistribution HR [sHR]: 1.04/mL; 95% CI: 1.01-1.08; <em>P</em> = 0.016), left circumflex coronary artery volume receiving 35 Gy with atrial flutter (sHR: 1.10/mL; 95% CI: 1.01-1.19; <em>P</em> = 0.028), PV volume receiving 55 Gy with SVT (sHR: 1.03 per 1%; 95% CI: 1.02-1.05; <em>P</em> &lt; 0.001), right coronary artery volume receiving 25 Gy with bradyarrhythmia (sHR: 1.14/mL; 95% CI: 1.00-1.30; <em>P</em> = 0.042), and left main coronary artery volume receiving 5 Gy with VT or asystole (sHR: 2.45/mL; 95% CI: 1.21-4.97; <em>P</em> = 0.013).</p></div><div><h3>Conclusions</h3><p>This study revealed pathophysiologically distinct arrhythmia classes associated with radiotherapy dose to discrete cardiac substructures, including PV dose with AF and SVT, left circumflex coronary artery dose with atrial flutter, right coronary artery dose with bradyarrhythmia, and left main coronary artery dose with VT or asystole, guiding potential risk mitigation approaches.</p></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 4","pages":"Pages 544-556"},"PeriodicalIF":12.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666087324002266/pdfft?md5=1c76e9e7009b792d3a7f1a38047cd97c&pid=1-s2.0-S2666087324002266-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142011400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}